NHS England (London) is seeking to identify professional, capable Providers to deliver the Abdominal Aortic Aneurysm Screening Programme (AAASP) across South London which also includes East Surrey and parts of Surrey Downs CCGs. One contract will be awarded (one tender Lot).
The contract will be part block and part activity based. The block will ensure all costs are covered to support service delivery to current performance standards (75% uptake). A tariff payment per screen will be offered for all men screened, who are part of the eligible cohort for that year, where uptake performance exceeds 75%. The maximum value of the block element is based on 75% uptake including self-referrals and surveillance (based on figure form 2018/19): Total – £755,000 per year for years 1-3 and £695,000 for year 4 (ex VAT).
This associated tariff payment will be £60 per screen (up to a maximum payment of £227,000 per year).
This will cover;
• Initial screens
• Surveillance screens
• Non-visualised screens below the acceptable level set by the National AAASP (per year)
The tender submission deadline is 12:00 (noon) on 18th December 2018 .
The contract start date is 1st September 2019. The contract period will be 3 years (36 months) followed by an optional extension of up to 1 year (12 months). Therefore the maximum contract duration, including available extensions, is 4 years (48 months). Award will be made against The NHS Standard Contract (currently 2017-2019, we expect these terms to be updated during this procurement so it may be necessary to contract against the revised version. Should this be the case then we will publish the revised version via the portal in advance of any award).
The Service Provider will: Invite eligible men to the AAASP using standard information provided by Public Health England (PHE); provide clear, high quality information that is accessible to all; carry out high quality abdominal ultrasound on those men attending for initial or follow-up screening according to national protocol; minimise any adverse effects of screening, including anxiety and unnecessary investigations; identify Abdominal Aortic Aneurysm’s accurately; enable men to make an informed choice about the management of their Abdominal Aortic Aneurysm; ensure appropriate and effective management of cardiovascular risk factors identified through screening; ensure referral to accredited vascular services for high quality diagnostic and treatment services; promote audit and research and learn from the results. The Services will be subject to an annual PHE Quality Assurance (QA) review and effectiveness of treatment will be monitored via annual reports of a National Vascular Review.